All Articles

Osisko Development is betting big on BC's historic Cariboo region, launching a massive drilling program to uncover new gold and expand its flagship project.

A new clinical trial in Malaysia could democratize advanced cancer care, testing an affordable, donor-derived immunotherapy challenging costly personalized treatments.

Enterprises lose up to 9% of revenue from missed contract obligations. New AI tools are turning static legal documents into actionable intelligence.

Fate Therapeutics' latest data suggests its iPSC-derived CAR-T could revolutionize lupus care, moving cell therapy beyond cancer and into the mainstream.

A new wave of affordable, user-friendly robots is here. A new mower ditches complexity, but what are the strategic trade-offs for consumers and the market?

Toshiba partners with a 38-year local veteran in Trinidad & Tobago. We analyze the strategy behind a deal that's more than just printers—it's a play for an entire region.

A key regulatory step for Hadron Energy's micro-reactor, backed by a unique SPAC model, signals a high-stakes bet on the future of U.S. energy.

FBI data shows most active threats begin outdoors. New tech is extending security beyond the building, creating an integrated, automated defense.

After crossing $1B in assets, a community bank adds a healthcare PE expert to its board. This is more than a hire—it's a new strategy for growth.

In a stunning strategic shift, Transcontinental sells its largest division to ProAmpac, rewarding shareholders and refocusing on its printing roots.

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

A $1M deal between two junior miners isn't just about cash; it’s a strategic pivot that could offer a new blueprint for funding discovery.

A deepening corporate governance battle pits STAAR Surgical's board against its largest shareholder and all major proxy firms over a $1.5B Alcon deal.

SAB Biotherapeutics' novel T1D therapy shows promise with a unique safety profile, challenging the status quo and offering new hope for patients.

Onex cashes out of Ryan Specialty with a stunning 49% IRR. We dive into the strategy behind the $1.2B exit and what it signals for specialty insurance.

EyeYon Medical's synthetic corneal implant, EndoArt, just got FDA approval for U.S. trials, offering a fix for the global donor tissue shortage.

As CEO J.K. Symancyk prepares for a key investor conference, Signet Jewelers' new strategy faces the test of a market transformed by tech and ethics.

Advanced aerial surveys reveal massive, untapped deposits of copper and nickel in Canada's far north, potentially rivaling the world's largest mineral reserves.

A top care provider changes hands not by choice, but by debt. What does Colisée's fate reveal about the risks of private equity in social care?

ATI Inc. names operational veteran Rob Foster as its new CFO, signaling a strategic bet that manufacturing prowess is the key to financial success.